Implicated autoantibodies in a kidney disease

Autoantibodies: Detection, Pathogenicity and Health Implications

Volumn , Issue , 2012, Pages 1-35

  Barabas, Arpad Zsigmond ^a   Cole, Chad Douglas ^b   Lafreniere, Rene ^a   Weir, Donald Mackay ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoimmunity; Membranous glomerulonephritis; Modified vaccination technique

Indexed keywords

EID: 84892065191     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (107)

1. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol., 2009, 5, 648-52.
2. Alballa S., Fritzler M., Davis P. A. case of drug induced lupus due to carbamazepine. J. Rheumatol., 1987, 14, 599-600.
3. Alousi MA., Post RS., Heymann W. Experimental autoimmune nephrosis in rats. Morphogenesis of the glomerular lesion: immunohistochemical and electron microscopic studies. Am. J. Pathol., 1969, 54, 47-71.
4. Andreakos E., Taylor PC., Feldmann M. Monoclonal antibodies in immune and inflammatory diseases. Curr. Opin. Biotechnol., 2002, 13, 615-20.
5. Andres G., Brentjens JR., Caldwell PR., Camussi G., Matsuo S. Formation of immune deposits and disease. Lab Invest, 1986, 55, 510-20.
6. Arbuckle MR., McClain MT., Rubertone MV., Scofield RH; Dennis GJ., James JA. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med., 2003, 349, 1526-33.
7. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today, 1991, 12, 154-9.
8. Barabas AZ., Cole CD., Barabas AD., Bahlis NJ., Lafreniere R. New vaccination technology for endogenous antigen-derived ailments. IDrugs, 2008, 11, 111-5.
9. Barabas AZ., Cole CD., Barabas AD., Bahlis NJ., Lafreniere R. A. vaccination technique to combat presently untreatable chronic ailments. BioProcessing Journal, 2007, 6, 12-8.
10. Barabas AZ., Cole CD., Barabas AD., Barabas AN., Lafreniere R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin. Dev. Immunol., 2006, 13, 17-24.
11. Barabas AZ., Cole CD., Barabas AD., Cowan JM., Yoon CS., Waisman DM et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int. J. Exp. Pathol., 2004, 85, 201-12.
12. Barabas AZ., Cole CD., Barabas AD., Graeff RM., Lafreniere R., Weir DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun. Rev., 2009, 8, 552-7.
13. Barabas AZ., Cole CD., Barabas AD., Graeff RM., Lafreniere R., Weir DM. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scandinavian Journal of Immunology, 2010, 71, 125-33.
14. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int. J. Exp. Pathol., 2003, 84, 245-58.
15. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int. J. Exp. Pathol., 2004, 85, 321-34.
16. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int. J. Exp. Pathol., 2004, 85, 277-85.
17. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol. Int., 2006, 56, 181-90.
18. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. A. modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann. N. Y. Acad. Sci., 2007, 1110, 619-29.
19. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics: Targets and Therapy, 2007, 1, 59-68.
20. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. An experimental autoimmune kidney disease caused by pathogenic autoantibodies. In Petrelli C, editor. New research on autoantibodies. Hauppauge NY: Nova Science Publishers, Inc., 2008, 151-72.
21. Barabas AZ., Cole CD., Barabas AD., Lafreniere R. Pathogenic and nonpathogenic autoimmune events-the good and/or the bad? In Dubois Q, editor. Autoantibodies research progress. Hauppauge NY: Nova Science Publishers, Inc., 2008, 9-18.
22. Barabas AZ., Cole CD, Kovacs ZB., Lafreniere R. Elevated antibody response by antigen presentation in immune complexes. Med. Sci. Monit., 2007, 13, BR119-BR124.
23. Barabas AZ., Cole CD., Lafreniere R., Weir DM. A new vaccination method for exogenous and endogenous antigen initiated disorders. In Bezio AI, Campbell BE, editors. Vaccinations: Procedures, Types and Controversy. Hauppauge NY: Nova Science Publishers, Inc., 2012, 1-25.
24. Barabas AZ., Cole CD., Weir DM., Lafreniere R. Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self. In Petrov M, editor. Autoimmune disorders: symptoms, diagnosis and treatment. Hauppauge NY: Nova Science Publishers, Inc., 2011, 35-66.
25. Barabas AZ., Cole CD., Weir DM., Lafreniere R. The primary target antigenic site in Heymann nephritis is the renal proximal convoluted tubules' brush border associated zone of cells. In Petrov M, editor. Autoimmune Disorders: Symptoms, Diagnosis and Treatment. Hauppauge NY: Nova Science Publishers, Inc., 2011, 281-92.
26. Barabas AZ., Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun. Rev., 2005, 4, 565-70.
27. Barabas AZ., Lannigan R. Auto-immune nephritis in rats. J. Pathol., 1969, 97, 537-43.
28. Barabas AZ., Nagi AH., Lannigan R., Womersley RA. The effect of cortisone treatment on autologous immune complex glomerulonephritis in rats. Br. J. Exp. Pathol., 1970, 51, 541-6.
29. Batsford SR., Weghaupt R., Takamiya H., Vogt A. Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron, 1985, 41, 146-51.
30. Bhan AK., Schneeberger EE., Baird LG., Collins AB., Kamata K., Bradford D et al. Studies with monoclonal antibodies against brush border antigens in Heymann nephritis. Lab Invest, 1985, 53, 421-32.
31. Blank M., Shoenfeld Y. B cell targeted therapy in autoimmunity. J. Autoimmun., 2007, 28, 62-8.
32. Boes M., Schmidt T., Linkemann K., Beaudette BC., Marshak-Rothstein A., Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc. Natl. Acad. Sci. US, 2000, 97, 1184-9.
33. Byrd JC., Waselenko JK., Maneatis TJ., Murphy T., Ward FT., Monahan BP et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol., 1999, 17, 791-5.
34. Challice J., Barabas AZ., Cornish J., Bruce JW., Lannigan R. Passive Heymann nephritis in pre-and post-natal rats. Br. J. Exp. Pathol., 1986, 67, 915-24.
35. Chastain EM., Miller SD. Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease. Immunol. Rev., 2012, 245, 227-38.
36. Disis ML., Shiota FM., Cheever MA. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology, 1998, 93, 192-9.
37. Dorner T., Radbruch A., Burmester GR. B-cell-directed therapies for autoimmune disease. Nat. Rev. Rheumatol., 2009, 5, 433-41.
38. Ebringer A. Molecular mimicry as the basis of a new theory of autoimmunity. In Zouali M, editor. Frontiers in Autoimmunity: fundamental aspects and clinical perspectives. Amsterdam Netherlands: IOS Press, 2003, 79-99.
39. Ebringer A., Thorpe C., Pirt J., Wilson C., Cunningham P., Ettelaie C. Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens? Environ. Health Perspect., 1997, 105, 1172-4.
40. Edgington TS., Glassock RJ., Dixon FJ. Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J. Exp. Med., 1968, 127, 555-72.
41. Edgington TS., Glassock RJ., Watson JI., Dixon FJ. Characterization and isolation of specific renal tubular epithelial antigens. J. Immunol., 1967, 99, 1199-210.
42. Feldmann M., Steinman L. Design of effective immunotherapy for human autoimmunity. Nature, 2005, 435, 612-9.
43. Ghaussy NO., Sibbitt WL., Jr.; Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J. Rheumatol., 2001, 28, 2449-53.
44. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am. J. Kidney Dis., 2010, 56, 157-67.
45. Glassock RJ., Edgington TS., Watson JI., Dixon FJ. Autologous immune complex nephritis induced with renal tubular antigen. II. The pathogenetic mechanism. J. Exp. Med., 1968, 127, 573-88.
46. Gonzalez-Cabrero J., de Nicolas R., Ortiz A., Mampaso F., Hernando L., Egido J. Presence of circulating antibodies against brush border antigens (Fx1A) in a patient with membranous nephropathy and bilateral pyeloureteral stenosis. Comparison with idiopathic membranous nephropathy. Nephrol. Dial. Transplant., 1992, 7, 293-9.
47. Greenwald P., Clifford CK., Milner JA. Diet and cancer prevention. Eur. J. Cancer, 2001, 37, 948-65.
48. Grupe WE; Kaplan MH. Demonstration of an antibody to proximal tubular antigen in the pathogenesis of experimental autoimmune nephrosis in rats. J Lab Clin Med, 1969, 74, 400-9.
49. Gullstrand B., Martensson U., Sturfelt G., Bengtsson AA., Truedsson L. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin. Exp. Immunol., 2009, 156, 303-11.
50. Heymann W., Hackel DB., Harwood S., Wilson SG., Hunter JLP. Production of nephritic syndrome in rats by Freund's adjuvant and rat kidney suspensions. Proc. Soc. Exp. Biol. Med., 1959, 100, 660-4.
51. Heymann W., Kmetec EP., Wilson SG., Hunter JLP., Hackel DB., Cuppage F. Experimental autoimmune renal disease in rats. In Grabar P, Miescher PA, editors. IIIrd International Symposium of Immunopathology. Switzerland: Schwabe and Co., Basel, 1963, 240-51.
52. Hogan SL., Muller KE., Jennette JC., Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis., 1995, 25, 862-75.
53. Jiang X., Khursigara G., Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science, 1994, 266, 810-3.
54. Kamata K., Baird LG., Erikson ME., Collins AB., McCluskey RT. Characterization of antigens and antibody specificities involved in Heymann nephritis. J. Immunol., 1985, 135, 2400-8.
55. Kerjaschki D. Molecular development of immune deposits and proteinuria in Heymann nephritis. Clin. Investig., 1993, 71, 817-21.
56. Kerjaschki D. Pathogenetic concepts of membranous glomerulopathy (MGN). J. Nephrol. 2000, 2000, 13, S96-100.
57. Kerjaschki D., Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl. Acad. Sci. US, 1982, 79, 5557-81.
58. Kerjaschki D., Farquhar MG. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J. Exp. Med., 1983, 157, 667-86.
59. Kerjaschki D., Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J. Am. Soc. Nephrol., 1996, 7, 2518-26.
60. Lannigan R., Barabas AZ., Peters K., Hardwick J. Some experimental models of the nephrotic syndrome. In Bajusz E, Jasmin G, editors. Meth. Achievment Experimental Pathology. New York: Karger, Basel, 1969, 141-70.
61. Leandro MJ., Edwards JC., Cambridge G; Ehrenstein MR., Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis. Rheum., 2002, 46, 2673-7.
62. Lin TS. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. Clin. Lymphoma Myeloma, 2008, 8 Suppl 4, S137-S143.
63. Lollini PL., Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol. Immunother., 2002, 51, 409-16.
64. Manson JJ., Mauri C., Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin. Immunopathol., 2005, 26, 425-32.
65. Manz RA., Arce S., Cassese G., Hauser AE,. Hiepe F., Radbruch A. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol., 2002, 14, 517-21.
66. Marr LA., Gilham DE., Campbell JD., Fraser AR. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin. Exp. Immunol., 2012, 167, 216-25.
67. Matsukawa W., Hara S., Yoshida F., Suzuki N., Fukatsu A., Yuzawa Y et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. J. Lab Clin. Med., 1992, 119, 116-23.
68. Mendrick DL., Noble B., Brentjens JR., Andres GA. Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int., 1980, 18, 328-43.
69. Mevorach D., Mascarenhas JO., Gershov D., Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J. Exp. Med., 1998, 188, 2313-20.
70. Mokhtarian F., Zhang Z., Shi Y., Gonzales E., Sobel RA. Molecular mimicry between a viral peptide and a myelin oligodendrocyte glycoprotein peptide induces autoimmune demyelinating disease in mice. J. Neuroimmunol., 1999, 95, 43-54.
71. Molina V., Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity, 2005, 38, 235-45.
72. Naruse T., Fukasawa T., Hirokawa N., Oike S., Miyakawa Y. The pathogenesis of experimental membranous glomerulonephritis induced with homologous nephritogenic tubular antigen. J. Exp. Med., 1976, 144, 1347-62.
73. Naruse T., Fukasawa T., Miyakawa Y. Laboratory model of membranous glomerulonephritis in rats induced by pronase-digested homologous renal tubular epithelial antigen. Lab Invest, 1975, 33, 141-6.
74. Neale TJ., Couser WG., Salant DJ., Lowenstein LM., Wilson CB. Specific uptake of Heymann's nephritic kidney eluate by rat kidney: studies in vivo and in isolated perfused kidneys. Lab Invest, 1982, 46, 450-3.
75. Noble B., Van Liew JB., Brentjens JR., Andres GA. Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest, 1982, 47, 427-36.
76. Ogden CA; Kowalewski R; Peng Y; Montenegro V; Elkon KB. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity, 2005, 38, 259-64.
77. Orbach H., Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, LaUSnne, Switzerland. Autoimmun. Rev., 2007, 6, 261-6.
78. Orlando RA., Farquhar MG. Identification of a cell line that expresses a cell surface and a soluble form of the gp330/receptor-associated protein (RAP) Heymann nephritis antigenic complex. Proc. Natl. Acad. Sci. US, 1993, 90, 4082-6.
79. Perna A., Schieppati A., Zamora J., Giuliano GA., Braun N., Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney Dis., 2004, 44, 385-401.
80. Perosa F., Favoino E., Caragnano MA., Prete M., Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun. Rev., 2005, 4, 526-31.
81. Pinckard RN., Weir DM. Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin. Exp. Immunol., 1966, 1, 33-43.
82. Quartier P., Potter PK., Ehrenstein MR., Walport MJ., Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur. J. Immunol., 2005, 35, 252-60.
83. Radbruch A., Muehlinghaus G., Luger EO., Inamine A., Smith KG., Dorner T et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol., 2006, 6, 741-50.
84. Raychowdhury R., Zheng G., Brown D., McCluskey RT. Induction of Heymann nephritis with a gp330/megalin fusion protein. Am. J. Pathol., 1996, 148, 1613-23.
85. Robinson MK., Shaller C., Garmestani K., Plascjak PS., Hodge KM., Yuan QA et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin. Cancer Res., 2008, 14, 875-82.
86. Ronco P., Debiec H. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Semin. Immunopathol., 2007, 29, 445-58.
87. Ronco P., Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J. Am. Soc. Nephrol., 2010, 21, 564-9.
88. Ronco P., Neale TJ., Wilson CB., Galceran M., Verroust P. An immunopathologic study of a 330-kD protein defined by monoclonal antibodies and reactive with anti-RTE alpha 5 antibodies and kidney eluates from active Heymann nephritis. J. Immunol., 1986, 136, 125-30.
89. Schulze C., Munoz LE., Franz S., Sarter K., Chaurio RA., Gaipl US et al. Clearance deficiency--a potential link between infections and autoimmunity. Autoimmun. Rev., 2008, 8, 5-8.
90. Shoenfeld Y., Gilburd B., Abu-Shakra M., Amital H., Barzilai O., Berkun Y et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases--2008. Isr. Med. Assoc. J., 2008, 10, 3-7.
91. Shoenfeld Y., Zandman-Goddard G., Stojanovich L., Cutolo M., Amital H., Levy Y et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008. Isr. Med. Assoc. J., 2008, 10, 8-12.
92. Singh AK., Makker SP. Circulatory antigens of Heymann nephritis. I. Identification and partial characterization. Immunology, 1986, 57, 467-72.
93. Singh AK., Schwartz MM. Circulatory antigen of Heymann nephritis. II. Isolation of a 70,000 MW antigen from normal rat serum which cross-reacts with Heymann nephritis antigen. Immunology, 1986, 59, 451-8.
94. Totoritis MC., Rubin RL. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad. Med., 1985, 78, 149-61.
95. Tsukada Y., Ono K., Maezawa A., Yano S., Naruse T. A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border--studies with a monoclonal antibody against pronase-digested tubular antigen. Clin. Exp. Immunol., 1994, 96, 303-10.
96. Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun. Rev., 2009, 8, 400-4.
97. Weir DM. Immunological reaction after tissue injury. Lancet, 1964, 1, 749-50.
98. Weir DM. The immune response after tissue injury. Pathol. Eur., 1966, 1, 108-18.
99. Weir DM. The immunologicial consequences of cell death. Lancet, 1967, 2, 1071-3.
100. Weir DM. Altered antigens and autoimmunity. Vox. Sang., 1969, 16, 304-13.
101. Weir DM; Elson CJ. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum., 1969, 12, 254-60.
102. Weir DM., Pinckard RN. Failure to induce tolerance to rat tissue antigens. Immunology, 1967, 13, 373-80.
103. Weir DM., Pinckard RN., Elson CJ.,Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin. Exp. Immunol., 1966, 1, 433-42.
104. Wermeling F., Karlsson MC., McGaha TL. An anatomical view on macrophages in tolerance. Autoimmun. Rev., 2009, 9, 49-52.
105. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J. Clin. Invest., 2001, 108, 1097-104.
106. Yoshida T., Mei H; Dorner T., Hiepe F., Radbruch A., Fillatreau S et al. Memory B and memory plasma cells. Immunol. Rev., 2010, 237, 117-39.
107. Yung RL., Johnson KJ., Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest, 1995, 73, 746-59.